Экспрессия молекулярно-биологических маркеров при аденокарциномах поджелудочной железы

Pancreatic adenocarcinoma is generally considered to be incurable by available treatment modalities with a 5-year survival rate of less that 4 %. Existing biomarkers are often inadequate. This article focuses on identification of biomarkers depending on the localization of cancer in pancreas. 53 patients were enrolled in this study. The high expression of angiogenic factors including TP (77,3 %) and VEGF (59,1 %) was observed in head of pancreas. The high proliferative activity of tumor (52,6 %) was the feather of piece and tail of pancreatic aadenocarcinoma. In this region, we have also observed the high expression COX-2 (68,4 %) and TP (57,9 %). Among the tested biomarkers the expression of Bcl-2 was of prognostic significance. 50 % of Bcl-2+ patients passed one year survival. The median of survival for Bcl-2 patients was 5±2 months, for Bcl-2+ patients 12±4 months (p=0,069). Based on data obtained, we conclude that the expression of these and other biomarkers will be valid to optimize the treatment of patients with pancreatic adenocarcinoma of different cancer localization.